Eli Lilly and

Company snapshot

Eli Lilly and maintains 62 tracked programs across Ulcerative Colitis, Diabetes Mellitus, Type 2, Breast Neoplasms, Non Small Cell Lung Cancer, Systemic Lupus Erythematosus, Obesity, Atopic Dermatitis, Non-Small Cell Lung Cancer, Benign Prostate Hyperplasia, Breast Cancer, Metastatic Breast Cancer, Systemic Juvenile Idiopathic Arthritis. Momentum score: 20/100 (30-day delta: n/a). Public registry

• 62 active pipeline program(s) linked via ClinicalTrials.gov.
• 62 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Eli Lilly and. Not investment advice.

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 50

• Peer + 0 momentum

  Lakefront Biotherapeutics NV

  TA overlap score 49.8

• Peer + 0 momentum

  Pfizer

  TA overlap score 49.6

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 40

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  HOFFMANN-LA ROCHE

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Eli Lilly and.

1. Jun 8, 2026 Clinical update

   premeal insulin lispro mixtures — Approved

2. Jun 8, 2026 Clinical update

   Pemetrexed — Phase 3

3. Jun 8, 2026 Clinical update

   pemetrexed — Phase 3

4. Jun 8, 2026 Clinical update

   Orforglipron — Phase 3

5. Jun 8, 2026 Clinical update

   Mirikizumab - Intravenous (IV) — Phase 2

View all clinical trial activity →

• What is Eli Lilly and?

  Eli Lilly and is a pharma organization headquartered in GURGAON, CN. Primary therapeutic focus areas include Ulcerative Colitis, Diabetes Mellitus, Type 2, Breast Neoplasms, Non Small Cell Lung Cancer, Systemic Lupus Erythematosus. NovaPharmaNews links 62 clinical program(s), 0 d

• Is Eli Lilly and publicly traded?

  Eli Lilly and appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Eli Lilly and develop or market?

  We link 42 drug profile(s) where Eli Lilly and is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eli-lilly-and-company-limited#company-drugs.

• What are the latest developments for Eli Lilly and?

  In the last 12 months our linked public records show 62 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Eli Lilly and focus on?

  Eli Lilly and focuses on Ulcerative Colitis, Diabetes Mellitus, Type 2, Breast Neoplasms based on our analysis of their pipeline programs and drug development activities.